Clinical Research Directory
Browse clinical research sites, groups, and studies.
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
Sponsor: Wenjin Yin
Summary
This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
Official title: Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: a Prospective, Randomised, Controlled, Multicentre Clinical Trial
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
123
Start Date
2025-09-25
Completion Date
2028-03
Last Updated
2025-11-18
Healthy Volunteers
No
Conditions
Interventions
QL1706
QL1706 is a single bifunctional MabPair product consisting of two engineered monoclonal antibodies (anti-PD-1 and anti-CTLA-4).
CDK4/6 inhibitor
palbociclib OR ribociclib OR abemaciclib OR dalpiciclib
Fulvestrant
SERD
Locations (1)
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China